Paper Details

  1. Home
  2. Paper Details

Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months.

Author: KhooT K, TanK K, TeoS K

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 4-month daily or combined regimen appears to be highly effective in the treatment of non-immunocompromised patients with smear- and culture-negative PTB.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Most patients with active pulmonary tuberculosis (PTB) are treated with a 6-month short course regimen. The purpose of the present study was to assess the efficacy of using 4 months of chemotherapy to treat patients with smear-negative PTB. METHODS: A total of 314 patients were random...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11957554

データ提供：米国国立医学図書館（NLM）

Four-Month Chemotherapy for Smear-Negative Pulmonary Tuberculosis

This research embarks on a journey through the complex world of tuberculosis (TB) treatment, investigating the efficacy of shortened chemotherapy regimens for patients with smear-negative pulmonary TB. The researchers, like intrepid explorers navigating a treacherous desert, sought to uncover alternative pathways for effective TB treatment. Their findings suggest that a 4-month chemotherapy regimen may be highly effective in treating non-immunocompromised patients with smear- and culture-negative TB, offering a potentially shorter and more convenient treatment option.

Efficacy of Shortened Chemotherapy for TB

The study found that both a 4-month daily and combined regimen were highly effective in treating smear- and culture-negative TB. This discovery is like finding a hidden oasis in the vast desert of TB research, offering a potentially shorter and more convenient treatment option for patients. The researchers' findings suggest that a 4-month regimen could be a viable alternative to the traditional 6-month regimen, potentially improving patient adherence and reducing treatment burden.

Optimizing TB Treatment: A Multifaceted Approach

This research underscores the importance of a multifaceted approach to optimizing TB treatment, including exploring shorter and more convenient regimens for selected patients. It's like utilizing a combination of tools and strategies to navigate the intricate landscape of TB treatment. The researchers' findings highlight the need for ongoing research to develop effective and patient-centered treatment options, ensuring the best possible outcomes for those living with TB.

Dr. Camel's Conclusion

This research provides a promising step towards optimizing TB treatment, highlighting the potential of shortened chemotherapy regimens for selected patients. It's like finding a hidden oasis in the vast desert of TB research, offering a potentially shorter and more convenient treatment option. The researchers' findings suggest that a 4-month regimen could be a viable alternative to the traditional 6-month regimen, potentially improving patient adherence and reducing treatment burden.

Date :
  1. Date Completed 2002-10-10
  2. Date Revised 2020-08-25
Further Info :

Pubmed ID

11957554

DOI: Digital Object Identifier

11957554

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.